Curr Pharm Des 20:11261135 Sikiri P, Petek M, Ruman R, Seiwerth S, Grabarevi Z, Rotkvi I, Turkovi B, Jagi V, Mildner B, Duvnjak M, Lang N, Danilovi Z, Cviko A, Kolega M, Sallmani A, Djai S, Bura M, Brki T, Bani M, Dodig M, Cori V, imievi V, Veljaca M, Erceg D, Jeek D, Simuni-Banek L, Skroza N, Buli K, Buljat G, Hanevaki M, Orihova V, Luinger D, Culig J, Separovi J, Marovi A, Mie S, Suchanek E, Matoz W, Perovi D, Gjurain M, Mikulandra S, Dernikovi K, Cuk V, Karakas I (1993) A new gastric juice peptide, BPC
Heres what the panels vote to expand peptide access could mean
A few commenters recommended that future performance targets should move towards shorter time periods as the quality gap closes
The key point: BPC-157 should only be considered with guidance from a licensed provider who understands peptide therapy, safety, and current regulations
XCI has been related to a greater threat of emerging autoimmune thyroid conditions